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One-sentence summary: Analysis of the cancer-associated fibroblast secretome identifies an 
angiogenesis-promoting factor. 
 
Editor’s summary: 
The secret(ing) life of the tumor stroma 
The hypoxia that develops in solid tumors leads to the formation of a dysfunctional vasculature that 
enables cancer cell survival and also prevents efficient chemotherapeutic penetration. Cancer-
associated fibroblasts (CAFs) in the tumor stroma release important angiogenic signals; however, the 
proteins secreted by these cells have generally been characterized at the genome level. Kugeratski et al. 
analyzed the proteome and secretome of CAFs and found that hypoxia altered the secretome of these 
cells. The authors identified a previously uncharacterized protein that they renamed HIAR. HIAR was 
increased in abundance in hypoxic CAFs, promoted the release of the pro-angiogenic factor VEGF from 
CAFs, and induced VEGF-dependent signaling in endothelial cells. These results provide an overview 
of the CAF secretome at the protein level and a new potential target for anti-angiogenic therapy. 
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Abstract 
Intratumoral hypoxia causes the formation of dysfunctional blood vessels, which contribute to tumor 
metastasis and reduce the efficacy of therapeutic treatments. Blood vessels are embedded in the 
tumor stroma of which cancer-associated fibroblasts (CAFs) constitute a prominent cellular 
component. We found that hypoxic human mammary CAFs promoted angiogenesis in CAF-endothelial 
cell co-cultures in vitro. Mass spectrometry-based proteomic analysis of the CAF secretome unraveled 
that hypoxic CAFs contributed to blood vessel abnormalities by altering their secretion of various pro- 
and anti-angiogenic factors. Hypoxia induced pronounced remodeling of the CAF proteome, including 
proteins that have not been previously related to this process. Among those, the uncharacterized 
protein NCBP2-AS2 that we renamed HIAR (hypoxia-induced angiogenesis regulator) was the protein 
most increased in abundance in hypoxic CAFs. Silencing of HIAR abrogated the pro-angiogenic and 
pro-migratory function of hypoxic CAFs by decreasing secretion of the pro-angiogenic factor VEGFA 
and consequently reducing VEGF/VEGFR downstream signaling in the endothelial cells. Our study has 
identified a regulator of angiogenesis and provides a map of hypoxia-induced molecular alterations in 
mammary CAFs. 
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Introduction 
Intratumoral hypoxia favors tumor aggressiveness and is associated with risk of metastasis, limited 
response to therapies and poor clinical outcome. The tumor vasculature plays key roles in these 
processes. The uncontrolled growth of the cancer cells results in the rapid consumption of oxygen 
released by the adjacent vasculature, leading to the formation of intratumoral hypoxic regions. To 
counteract the lack of oxygen, hypoxic cancer and stromal cells secrete factors that stimulate the 
recruitment of blood vessels, a process that is called angiogenesis (1). However, rather than promoting 
the formation of a functional vasculature, excessive amounts of those factors result in the recruitment 
of blood vessels that are leaky and nonfunctional. This phenomenon in turn leads to the expansion of 
hypoxic areas and the formation of a positive feedback loop between hypoxia and non-functional 
blood vessels that is detrimental and challenging to disrupt (2-4). So far, most of the effort has been 
devoted to targeting the vascular endothelial growth factor (VEGF) pathway (5), which is a potent 
inducer of blood vessel growth and is transcriptionally regulated by the hypoxia inducible factor 1α 
(HIF1α) (6). However, VEGF controls also the growth of blood vessels in normal tissues (7); therefore 
therapies that block VEGF signaling result in unwanted adverse effects (8). The identification of 
mechanisms that regulate blood vessel recruitment in hypoxic tumors may provide useful hints to 
develop strategies to block this feedback loop without interfering with the normal vasculature. Tumor 
blood vessels are typically embedded within the stroma, where cancer-associated fibroblasts (CAFs) 
are an abundant cell population (9). CAFs can originate from activation of resident normal fibroblasts 
within the tumor stroma and secrete factors that alter the composition and physical properties of the 
extracellular matrix (ECM) and signal to adjacent cells (10-12). CAFs play crucial roles in the 
pathogenesis of cancer, including the recruitment of blood vessels within the tumor (13, 14). How 
CAFs respond to oxygen deprivation is largely unknown and rather controversial. Intratumoral hypoxia 
induces CAF activation and HIF1α-activated fibroblasts co-transplanted in an MDA-MB-231 breast 
cancer xenograft are pro-tumorigenic and pro-metastatic (15). Conversely, tumorigenesis in a PyMT 
breast cancer model is accelerated by fibroblast-specific depletion of Hif1α before tumor onset, but 
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not by depletion of prolyl-hydroxylase 2 (Phd2), which stabilizes HIF1α (16, 17). Furthermore, 
decreasing PHD2 levels in CAFs reduces their activated phenotype and their pro-metastatic activity in 
a 4T1 breast cancer orthotopic model (18). A better understanding of the molecular mechanisms 
underpinning the response of CAFs to hypoxia could bring useful insights on the role of these cells in 
hypoxic tumors.  
Hypoxia-induced signaling has been mostly studied at the genome-wide gene expression level, and 
there is little information on how it affects the proteome of the cells. Modern mass spectrometry (MS) 
technology and robust platforms for data analysis allow in-depth and highly accurate quantitative 
analysis of cellular and sub-cellular proteomes (19-21), including those shaped by hypoxia (22, 23). 
Proteome-wide analysis of breast cancer cell-derived conditioned media (CM) has shown that high 
levels of lysyl oxidase (LOX) are induced by hypoxia and associated with bone metastasis, leading to 
the discovery of a role for LOX in bone metastasis formation (23). 
Here we have used three dimensional (3D) co-cultures of human primary endothelial cells with 
mammary CAFs and established that the secretome of hypoxic CAFs promotes endothelial cell 
sprouting, which is one of the initial steps of angiogenesis (24). We have identified proteomic 
alterations induced by hypoxia in CAFs using high resolution MS and stable isotope labelling with 
amino acids in cell culture (SILAC) (25). We found hundreds of regulated molecules that may support 
hypoxic CAFs to drive angiogenesis, and discovered a regulatory mechanism of VEGF signaling through 
which hypoxic but not normoxic CAFs control endothelial sprouting. 
Results 
The secretome of hypoxic CAFs promotes endothelial sprouting 
To determine how the hypoxic environment influences the ability of CAFs to regulate angiogenesis, 
we used an established three dimensional (3D) co-culture model in which collagen IV-coated beads 
are covered with endothelial cells and embedded into fibrin gel. CAFs are then plated on top of the 
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solidified gel and secrete factors that influence the sprouting and invasion of the endothelial cells 
though the 3D matrix (fig. 1A) (26). We used human umbilical vein endothelial cells (referred to as 
ECs) because they are a well-characterized model to study endothelial functions and angiogenesis (27, 
28). For fibroblasts, we used two human mammary CAF cell lines: cancer cell-induced CAFs (cCAFs) 
that we and others have previously characterized for their pro-angiogenic function in vitro and in vivo 
(13, 29) and patient-derived CAFs (pCAFs), which were isolated from a triple-negative invasive ductal 
carcinoma. The co-culture was exposed to either normoxia or hypoxia for 72h. Endothelial sprouting 
was enhanced by hypoxia in both co-cultures compared with their normoxic counterpart, as measured 
by the total number and length of EC sprouts and their migration area surrounding the bead (fig. 1B). 
To determine whether the factors secreted by hypoxic CAFs were the major contributor of this 
phenotype, normoxic ECs embedded in fibrin gel were treated with conditioned medium (CM) derived 
from cCAFs or pCAFs cultured under hypoxia or normoxia for 72h (fig. 1A). CAFs readily responded to 
hypoxia, because HIF1α was stabilized and accumulated into the nucleus after 4h of oxygen 
deprivation (fig. S1A,B). Moreover, after 72h of hypoxia, CAFs were still proliferative and not 
apoptotic, as measured by EdU incorporation (fig. S1C) and TUNEL assay (fig. S1D). Using this set-up, 
where there are no CAFs in the 3D culture and ECs are stimulated by CAF-derived CM, we observed a 
significant increase in sprouting when ECs were treated with the hypoxic CM (fig. 1C). Hence, hypoxic 
CAFs secrete factors that promote endothelial sprouting. 
Hypoxia increases the expression of the potent pro-angiogenic factor VEGFA, by activating the HIF 
pathway. As expected, hypoxia enhanced the mRNA levels and secretion of VEGFA in both cCAFs and 
pCAFs (fig 1D,E). To assess whether the pro-angiogenic effect of the CM from hypoxic CAFs was due 
to increased VEGFA levels, we blocked VEGFA/VEGFR signaling with the anti-VEGFA antibody 
bevacizumab. The addition of bevacizumab to the CM from hypoxic and normoxic CAFs reduced the 
sprouting of ECs by 60%, indicating that VEGF is a major contributor of the pro-angiogenic function of 
CAFs under either condition (fig. 1F). This finding was confirmed by the reduced sprouting observed 
upon HIF1α silencing in hypoxic CAFs (fig. S1E). Factors other than VEGF may also contribute to the 
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pro-angiogenic effect of the hypoxic CM, because even in the presence of bevacizumab, the CM from 
hypoxic CAFs enhanced endothelial sprouting (fig. 1F).  
Hypoxia remodels the proteome and secretome of CAFs to promote angiogenesis 
To determine the molecular events underpinning the pro-angiogenic function of hypoxic CAFs we used 
MS-based proteomics to compare the proteome of cCAFs and pCAFs cultured under normoxia or 
hypoxia for 72h, using SILAC for accurate protein quantification. We additionally analyzed the 
secretome of these cells to map the composition of the pro-angiogenic secretome of hypoxic CAFs. 
We measured the total cell proteome by fractionating with strong anion exchange chromatography 
tryptic peptides obtained from SDS-extracted proteins (30). We separated the CM into two fractions 
using multistep centrifugation: a fraction containing soluble factors (soluble) and a fraction containing 
extracellular vesicles (EVs). All samples were measured on an Orbitrap mass spectrometer followed 
by analysis with the MaxQuant computational platform (31) (fig. 2A). Overall 3,513 proteins were 
robustly quantified in the cell proteome (in at least two out of three biological replicates in both cCAFs 
and pCAFs), 681 proteins in the soluble secretome and 165 proteins in the EV fraction (Data File S1). 
Because we found that replicates strongly correlated with each other (fig. S1F), for each protein we 
averaged the hypoxia/normoxia SILAC ratio between replicates; proteins were defined as hypoxia-
regulated based on the standard deviation of their ratio from the mean SILAC ratio calculated for the 
entire dataset. We classified regulated proteins as strongly regulated when the hypoxia/normoxia 
ratio was greater than two standard deviations (SD) from the mean, or as modestly regulated when 
the hypoxia/normoxia ratio was between one and two SDs. The latter group contained well-
established HIF1α-target genes, such as CXCL12, lysyl oxidase-like 2 (LOXL2), procollagen-lysine,2-
oxoglutarate 5-dioxygenase 2 (PLOD2) and prolyl 4-hydroxylase subunit alpha-1 (P4HA1), among 
others (32-34) (Data File S1,S2), supporting the choice of this threshold to identify hypoxia-controlled 
proteins in our study. We required proteins to be regulated in both cCAFs and pCAFs. With these 
criteria, we identified 124 upregulated and 221 downregulated proteins by hypoxia in the intracellular 
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proteome, and 27 upregulated and 34 downregulated proteins in the secretomes (fig. S2A). The 
physical and functional interactions between these proteins and the enriched functional categories 
showed that a vast proportion mirrored the metabolic reprogramming required for cellular adaptation 
to reduced oxygen availability (fig. 2B). Hypoxia increased the levels of proteins involved in glycolysis, 
while decreased levels of those involved in oxidative phosphorylation. Additionally, this analysis 
revealed a significant regulation of extracellular proteins, such as those located in the ECM or in 
exosomes and extracellular vesicles (fig. 2B), thus underlining the impact that hypoxia exerts on the 
ability of CAFs to alter the surrounding environment. In addition, we pinpointed the angiogenesis-
regulating factors that were secreted by hypoxic CAFs. These included staniocalcin 1 (STC1), LOXL2 
(32, 35), CXCL12 (14), annexin 1 and 2 (36, 37) and the endotrophin fragment of collagen 6-alpha (38), 
all of which were upregulated by hypoxia (fig. S2A,B). We confirmed VEGFA, LOXL2 and STC1 
upregulation by RT-qPCR analysis (fig. S2C). Conversely, collagen fragments with anti-angiogenic 
properties, such as vastatin (COL8A1) (39), arresten (COL4A2) (40) and canstatin (COL4A1) (41), were 
down-regulated (fig. S2A,B).  
NCBP2-AS2 is a hypoxia-induced factor in CAFs 
Next, we exploited our data to identify mechanisms that underpin hypoxic CAF functions. We 
compared our hypoxia-induced proteomic signature with known HIF1α-responsive genes and publicly 
available hypoxia-related gene expression signatures (fig. S3A and Data File S2). More than 75% of our 
signature (300 proteins) was not identified as hypoxia-regulated at the gene expression level by any 
of the analyzed datasets. This result suggests that the extent of gene expression regulation was below 
the statistical threshold, or that these proteins are regulated by hypoxia either post-transcriptionally 
or specifically in CAFs. Supporting the hypothesis of post-transcriptional regulation, hypoxia down-
regulated pentraxin-related protein 3 (PTX3) and carboxypeptidase A4 (CPA4) at the protein but not 
at the gene expression level (fig. S3B,C). Moreover, we identified 134 mitochondrial proteins with 
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decreased levels in hypoxic CAFs (fig. S3A and Data File S2), indicating that hypoxia may also induce 
extensive mitochondrial damage in CAFs (22, 42). 
Within our signature, there were proteins concordantly regulated in both the proteome and 
secretome: COL1A1, COL6A2, COL14A1, LRRC17, NCBP2-AS2, SDC2 and VCAM1 (fig. S3A and Data File 
S2). These proteins could be important because they may have a strong impact not only on CAF 
functions, but also as paracrine factors on other cell types; moreover they could potentially be used 
as biomarkers for hypoxia. Of these, NCBP2-AS2 was strongly up-regulated by hypoxia in the proteome 
and soluble secretome of cCAFs and pCAFs (fig. 3A,B, Data File S2). Fewer peptides of NCBP2-AS2 were 
identified in the secretome than in the proteome (Data File S2), suggesting that NCBP2-AS2 is 
predominantly intracellular but also released as soluble factor. Increased levels of NCBP2-AS2 in total 
CAF lysate were confirmed using a targeted MS-based approach (fig. S4A-C). Conversely, we did not 
detect a correspondent increase in NCBP2-AS2 at the mRNA levels in hypoxic CAFs (fig. 3C, and fig 
S5A,B) or upon treatment with the HIF1α-stabilizing prolyl hydroxylase domain-containing protein 
inhibitor dimethyloxaloylglycine (DMOG) (fig. 3D). Conversely, NCBP2-AS2 translation increased with 
hypoxia. Ribosomal profiling analysis showed that normoxic and hypoxic CAFs had similar levels of 
total protein translation (fig. 3E). Furthermore, the amount of NCBP2-AS2 mRNA associated with 
polysomes, which are the actively translating subset of ribosomes, was significantly higher in hypoxic 
than in normoxic CAFs (Fig. 3F). We confirmed an increase in NCBP2-AS2 translation upon stimulation 
with hypoxia also using a pulsed-SILAC approach coupled to targeted MS-proteomics (fig. S6A). Thus, 
our findings indicate that hypoxia induces NCBP2-AS2 levels mostly post-transcriptionally, by 
enhancing its translation. 
Hypoxic CAFs promote angiogenesis through NCBP2-AS2  
To determine whether NCBP2-AS2 contributed to the pro-angiogenic function of hypoxic CAFs, we 
silenced NCBP2-AS2 in CAFs and assessed the pro-angiogenic function of their CM. ECs treated with 
the CM from hypoxic CAFs with NCBP2-AS2 silencing sprouted significantly less than those treated 
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with the CM from control CAFs. Conversely, the CM from normoxic CAFs control or those with NCBP2-
AS2 silencing promoted endothelial sprouting to a similar extent (Fig. 4A-D and fig. S6B). Of note, the 
sprouting induced by normoxic and hypoxic CAFs with NCBP2-AS2 silencing was comparable. Since we 
did not detect a significant increase in sprouting when the recombinant purified GST-tagged NCBP2-
AS2 was added to the medium of ECs cultured in 3D fibrin gel (fig. S7A), NCBP2-AS2 is likely to control 
endothelial sprouting by regulating intracellular CAF functions rather than as a paracrine factor. Next, 
we confirmed that NCBP2-AS2 supports the pro-angiogenic function of hypoxic CAFs also in vivo in a 
subcutaneous sponge assay typically used to investigate angiogenesis in vivo (43). In this assay, a 
sponge is subcutaneously implanted to initiate an inflammatory reaction that induces endothelial cell 
infiltration. This leads to the formation of a functional capillary network, whose extension is 
determined by the factors or conditioned medium contained in the sponge. The vessel density in 
sponges that were embedded with the CM from CAFs with NCBP2-AS2 silencing was significantly lower 
than in those containing the CM from control CAFs (fig. 4 E,F). 
Because sprouting angiogenesis is regulated by a combination of EC proliferation and migration, we 
investigated how NCBP2-AS2 silencing affected these functions. When treated with the CM from CAFs 
with or without NCBP2-AS2 silencing, EC proliferation in 3D and 2D culture was comparable, as 
measured by EdU incorporation (fig 5A-C, fig. S7B,C). Next, we established that the CM from hypoxic 
CAFs with NCBP2-AS2 silencing had reduced pro-migratory properties compared with the CM from 
hypoxic CAFs control. Wound closure in an endothelial monolayer was slower in ECs treated with CM 
from NCBP2-AS2-silenced hypoxic CAFs. Conversely, silencing of NCBP2-AS2 in normoxic CAFs had 
minor impact on the pro-migratory function of their secretome (fig. 5D-G). To confirm the role of 
NCBP2-AS2 in cell migration, we evaluated the ability of ECs to form lamellipodia, because pro-
angiogenic factors such as VEGF induce the formation of cell protrusions (44). To monitor lamellipodia, 
we performed immunostaining for cortactin, which is a cortical actin remodeling protein and major 
mediator of lamellipodia formation (45). The presence or absence of NCBP2-AS2 in hypoxic CAFs did 
not affect the total perimeter of ECs, but when treated with the CM from hypoxic CAFs with NCBP2-
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AS2 silencing the ECs had significantly fewer cortactin-enriched protrusions (fig. 5H-J). These data 
show that NCBP2-AS2 in CAFs is required to support the pro-angiogenic activity of their secretome. 
NCBP2-AS2 regulates VEGFA expression 
To understand how NCBP2-AS2 controls the pro-sprouting function of the CAF secretome, we used 
SILAC MS proteomics to identify molecular alterations induced upon silencing of NCBP2-AS2 in hypoxic 
CAFs. The knockdown of NCBP2-AS2 did not significantly alter the intracellular proteome of the CAFs 
(fig. 6A and Data File S3). Conversely, the levels of VEGFA in the secretome of CAFs silenced for NCBP2-
AS2 were down-regulated (fig. 6B and Data File S4), as also confirmed by ELISA (fig 6C, D). RT-qPCR 
analysis showed that VEGFA downregulation occurred also at transcriptional level (fig. 6E, F). VEGF 
levels in CAFs were not regulated in an autocrine manner by secreted NCBP2-AS2, because the amount 
of VEGFA in the secretome of hypoxic CAFs silenced for NCBP2-AS2 could not be rescued upon 
treatment with conditioned media from hypoxic control CAFs (fig S7D-F). Next, we investigated how 
other hypoxia-regulated pro- and anti-angiogenic factors were affected by NCBP2-AS2 silencing in 
CAFs. The levels of the pro-angiogenic protein STC1 decreased upon NCBP2-AS2 silencing, although at 
a lower extent compared to VEGFA, whereas the anti-angiogenic factor COL4A2 was modestly 
increased upon NCBP2-AS2 silencing (fig 6G). Thus STC1 and COL4A2 may also contribute to the 
decreased pro-angiogenic function of hypoxic CAFs. Together, these results show that VEGFA could 
account for most of the reduced pro-angiogenic effect of the secretome of CAFs with NCBP2-AS2 
silencing. 
We reasoned that reduced amounts of VEGFA in the CM from NCBP2-AS2-silenced hypoxic CAFs 
caused the reduction in sprouting observed in ECs treated with this CM. Defective sprouting in ECs 
was rescued by supplementing the CM from hypoxic NCBP2-AS2-silenced CAFs with VEGFA (fig 7A-C), 
thus confirming our hypothesis. Likewise, the addition of bevacizumab in the CM from hypoxic CAFs 
with NCBP2-AS2 silencing did not have an additive inhibitory effect on endothelial sprouting (fig. 7D-
F). Moreover, ECs treated with hypoxic CAF-derived CM had activated VEGFR2 and canonical 
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downstream signaling, as shown by phosphorylation of the regulatory site of PLCγ (Tyr783), AKT (Ser473) 
and ERK1/2 (Thr202/Tyr204). Conversely, the extent of VEGFR2 activation and the downstream signaling 
were reduced in ECs treated with CM from hypoxic CAFs silenced for NCBP2-AS2 (Fig. 7G,H and Fig. 
S8). Thus, we show that NCBP2-AS2 controls the pro-angiogenic function of CAF secretome by 
regulating VEGFA levels and that this, in turn, controls VEGF-dependent sprouting in ECs (Fig 7I). 
NCBP2-AS2 is expressed in human tumors 
Finally, we determined NCBP2-AS2 expression in publicly available TCGA datasets of breast cancer 
patient samples. While this analysis showed that NCBP2-AS2 is expressed in tumors, giving that 
NCBP2-AS2 regulation by hypoxia occurs predominantly at the post-transcriptional level, we could not 
find a positive correlation between NCBP2-AS2 gene expression levels and hypoxia (fig. S9). We then 
looked at NCBP2-AS2 expression in tissue microarray (TMA). Because antibodies that recognize 
NCBP2-AS2 by immunohistochemistry staining are not available, we assessed its expression by in situ 
hybridization. In a breast cancer TMA containing 108 patient samples, we observed NCBP2-AS2 
positive staining in the stroma of 10% of the tumors. In particular, ductal carcinomas positively stained 
for NCBP2-AS2 whereas no staining was detected in the stroma of lobular carcinomas. We found that 
3% of intraductal carcinoma and 14% of invasive ductal carcinoma positively stain for NCBP2-AS2 in 
the stroma (fig. 8A,B). These findings indicate that the frequency of NCBP2-AS2 expression in the 
stroma increases with the progression of the disease, suggesting a possible role in advanced disease. 
Discussion 
The ability of hypoxia to create an aberrant and dysfunctional tumor vasculature is underpinned by 
secreted pro-angiogenic factors that are downstream of HIF1α signaling, of which VEGF plays a key 
role. CAFs are highly abundant in invasive carcinomas where they create an aberrant 
microenvironment permissive for blood vessel growth. Notably, hypoxic and pro-angiogenic gene 
expression signatures found in the stroma of breast cancer patients correlate with poor clinical 
outcome (46), highlighting the importance of better understanding the role of hypoxia in the tumor 
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stroma. Here we showed that hypoxia exacerbated the pro-angiogenic functions of CAFs, and MS-
proteomic analyses pinpointed potential molecular mechanisms responsible for this function. VEGF is 
the major, but not the only, contributor of the enhanced pro-angiogenic activity of hypoxic CAFs, and 
we unveiled a mechanism through which NCBP2-AS2 controls VEGFA expression in hypoxic CAFs in 
vitro. 
The CAF secretome is unique for its complexity and ability to remodel the tumor microenvironment 
including recruiting blood vessels. The cCAF model used in this study has been previously exploited by 
us and others to determine that TGFβ and CXCL12 dependent pathways support the pro-angiogenic 
activity of these cells (13) and to uncover a pro-angiogenic function for the CAF-secreted protein 
chloride intracellular channel 3 (CLIC3) (29). Here we deployed cCAFs and patient-derived CAFs to 
draw an intracellular and extracellular molecular portrait of hypoxic mammary CAFs. We did not find 
significant changes in CAF activation marker αSMA (ACTA2 in Data File S1), indicating that in our cell 
models and experimental conditions hypoxia does not inactivate CAFs, as previously shown in head 
and neck and vulvar CAFs (18). Conversely, reduced oxygen availability remodels the CAF secretome. 
Hypoxic CAFs secrete increased amounts of pro-angiogenic factors and decreased amounts of anti-
angiogenic factors, conferring enhanced pro-angiogenic properties to their CM. We asked whether 
our datasets could be exploited to identify mechanisms that promote the pro-angiogenic effect of 
hypoxic CAFs. These could be potential targets to block the formation of a dysfunctional vasculature 
in hypoxic cancers. Proteins up-regulated by hypoxia and which were found also secreted by CAFs may 
be useful not only as targets but also as potential biomarkers in body fluids. We discovered the 
antisense gene protein NCBP2-AS2 (transcribed from the antisense DNA strand of the gene NCBP2-
AS2) as a hypoxia-responsive molecule. Hypoxia controls protein levels and regulates both 
transcription and translation mechanisms (47, 48). Notably, the latter promotes a swifter response to 
environmental stimuli. NCBP2-AS2 translation was enhanced by hypoxia, thus indicating that it may 
play key roles to counteract hypoxic stress in the cells, for example, boosting VEGFA signaling for the 
recruitment of blood vessels. We showed that targeting NCBP2-AS2 in hypoxic CAFs reduced VEGFA 
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expression and secretion to the levels of VEGFA expressed in normoxic CAFs, but that this 
manipulation did not affect the pro-angiogenic activity of normoxic CAFs in our in vitro setup. These 
results make it tempting to speculate that NCBP2-AS2 could offer a therapeutic opportunity to 
normalize the dysfunctional vasculature typical of hypoxic malignant cancers without altering 
physiological angiogenesis. Indeed, silencing NCBP2-AS2 in hypoxic CAFs significantly reduced the pro-
angiogenic activity of their CM in vivo. In situ hybridization for NCBP2-AS2 in breast cancer patient 
samples showed that it is expressed in the tumor stroma. This prompts investigation into the 
functional consequences of modulating the levels of stromal NCBP2-AS2 in cancer pathology in vivo. 
How NCBP2-AS2 controls VEGFA levels remains to be elucidated. STC1 may play a role because it was 
also found down-regulated in the CAF secretome in the absence of NCBP2-AS2. In gastric cancer, STC1 
promotes angiogenesis in vitro and in vivo by increasing VEGF expression through the activation of 
protein kinase C βII (PKCβII) and ERK1/2 pathways (49). Additional players are suggested by unbiased 
MS-based interactome analyses in HeLa cells (50) which identified the GTPase KRAS, the Ras-related 
protein Rab-5C (RAB5C), the nuclear cap-binding protein subunit 2 (NCBP2), the serine/threonine-
protein phosphatase 2A regulatory subunit B’’ subunit gamma (PPP2R3C), the kinesin-like protein 
KIF19 (KIF19), the RNA-binding protein 8A (RBM8A) and the survival motor neuron protein (SMN1) as 
potential binding partners of NCBP2-AS2. Of note, SMN1 and VEGF are upregulated in ischemic rat 
hippocampus (51) and VEGF expression is up-regulated by wild type KRAS in human colon carcinoma 
cells (52) and by mutant KRAS  in human colon carcinoma (53), pancreatic epithelial (54) and NIH3T3 
(55) cells. 
In conclusion, here we provide new insight into how mammary CAFs adapt to and behave in a low 
oxygen environment and provide a resource to discover molecular mechanisms underpinning CAF 
functions. Furthermore, we unraveled a mechanism through which hypoxic CAFs control the 
expression of the most potent pro-angiogenic factor, VEGF, through NCBP2-AS2, which we propose to 
rename to a more functional name, HIAR (hypoxia-induced angiogenesis regulator).  
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Materials and Methods 
Cell culture 
Human umbilical vein endothelial cells (HUVECs) were isolated in house from umbilical cords and 
cultured in EGM-2 medium (Lonza) on plastic dishes coated in 1% gelatin. Patient-derived mammary 
cancer-associated fibroblasts (pCAFs) were isolated in house from a grade 3 triple negative breast 
cancer patient sample obtained through NHS Greater Glasgow and Clyde Biorepository. All 
participants gave specific consent to use their tissue samples for research. The pCAFs were cultured 
on plastic dishes coated in 35 µg/ml collagen I (Gibco). The cancer cell-derived human mammary CAFs 
(cCAFs) cell line was kindly provided by Professor Akira Orimo (Paterson Institute, Manchester). The 
pCAFs, cCAFs and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, 
Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS, Life technologies), 1% 
glutamine (Life technologies) and 1% penicilin/streptomycin (Life technologies). For quantitative 
proteomics experiments, pCAFs and cCAFs were cultured in SILAC DMEM (Life Technologies) 
supplemented with 2% FBS, 8% 10 kDa dialysed FBS (PAA), 1% glutamine and 1% 
penicillin/streptomycin. SILAC DMEM used for the ‘medium’ labelled cells contained 84 mg/l 13C6 L-
arginine and 175 mg/l D4 L-lysine, whereas the medium for the ‘heavy’ labelled cells contained 84 
mg/l 13C615N4 L-arginine and 175 mg/l 13C615N2 L-lysine (Cambridge Isotope Laboratories). All the cell 
lines described above were kept in standard tissue culture incubators at 37 °C, 5% CO2 in 21% O2 
(normoxic condition) or in a hypoxic chamber at 37°C, 5% CO2 in 1% O2 (hypoxic condition). The 
hypoxic chamber utilized was a Whitley H30/H35 Hypoxystation (Don Whitley Scientific). All cell lines 
were routinely tested for mycoplasma. 
pCAFs isolation 
Tumour tissue was minced and transferred into a 10 cm culture dish. 10 ml of RPMI supplemented 
with 10% FCS, 1% fungizone (Life Technologies), 1% penicillin/streptomycin (Invitrogen) and activated 
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collagenase 1A (1 mg/ml, Sigma) were added and incubated overnight at 37 °C. The digested tissue 
was then filtered through a cell strainer and centrifuged. The CAF-containing cell pellet was washed 
in PBS, resuspended in DMEM, 10% FBS, 1% P/S, 1% fungizone, and plated on collagen coated (35 
µg/ml, rat tail collagen 1, Gibco) culture dish. Patient samples were obtained through NHS Greater 
Glasgow and Clyde Biorepository (project #305). All participants gave specific consent to use their 
tissue samples for research. 
pCAF immortalization 
The pCAFs were immortalized using a human telomerase reverse transcriptase (hTERT)-expressing 
plasmid (pIRES2-hygro), kindly provided by Dr. Fernando Calvo (ICR, London). Lentivirus-containing 
the hTERT plasmid were generated in HEK293T cells. Two rounds of viral transduction were performed 
on consecutive days. Cells were selected using 10 µg/ml hygromycin (Sigma). 
3D fibrin gel-based sprouting assay 
To assess the sprouting ability of ECs in 3D we have used a previously described protocol (26) with 
minor modifications (29). Around 3.3x105 ECs embedded in the fibrin gel were either treated with CAF-
derived conditioned medium (CM, prepared from CAFs cultured in 2D on plastic dish) or co-cultured 
with 2x104 CAFs in a 24-well plate. For the experiments where the CAF-derived CM was used, 900 µl 
of freshly collected CM derived from 8x104 CAFs cultured in EGM-2 for 72h under normoxia or hypoxia 
were admixed with 100 µl of fresh EGM-2. The CM was replaced with fresh CM every 24h. For 
experiments using VEGFA neutralizing antibody, 1 µg/ml of bevacizumab (Roche) or IgGK (Sigma) was 
added in the CM. For the rescue experiments, 50 ng/ml of VEGFA (Sigma) was added. For the 3D 
experiments, the images used for quantification were acquired using the Axiovert 25 microscope 
(Zeiss) with a Retiga EXi Fast 1394 camera (Imaging) two days after the beads were embedded in the 
fibrin gel. Three technical replicates were performed for each biological replicate. A total of 15 images 
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were acquired and quantified for each biological replicate. In total n=3 biological replicates (n=45 
images) were performed for each experiment. 
EdU proliferation assay 
5-ethynyl-2'-deoxyuridine (EdU, Life technologies) was added to the culture medium to a final 
concentration of 10 µM and cells were allowed to incorporate for 6 h, when cultured in 3D, and 1.5 h, 
when cultured in 2D. Following EdU incorporation, cells were fixed with 4% PFA for 15 min, washed 
twice with 3% BSA and permeabilized with 0.5% Triton-X for 20 min. EdU positive cells were 
fluorescently labelled using a click reaction following the manufactures’ instructions (Life 
technologies), whilst all cells were stained with DAPI. After the staining, images were acquired in the 
Nikon A1R confocal microscope for the 3D assay and in the Zeiss 710 confocal for 2D cultures. The 
percentage of cells that entered the S phase of the cell cycle was determined by dividing the number 
of EdU positive cells by the total number of cells positive for DAPI. 
TUNEL assay 
Click-iT TUNEL Alexa Fluor 488 Imaging Assay (Life technologies) was used to monitor DNA degradation 
in apoptotic cells. In a 24-well plate, 8x104 cells were seeded on a 13 mm coverslip. CAFs were exposed 
to hypoxia and fixed with 4% PFA for 15 min. Cells were permeabilized with 0.25% Triton X-100 in PBS 
for 20 min and the TUNEL assay was performed according to manufacturer’s instructions. 
Secretome production and analysis 
For the cCAF- and pCAF-derived secretome, 6x106 ‘medium’ and ‘heavy’ SILAC labelled cells were 
seeded in 15 cm dishes. The following day, cells were washed six times with pre-warmed PBS to 
remove FBS residuals, serum-free SILAC medium was added and cells were allowed to secrete for 72 
h in either normoxic or hypoxic conditions. Subsequently, the same volume of conditioned media from 
3 dishes from each condition was mixed and subjected to sequential centrifugations at 4°C: 300 x g 
for 10 min, 2,000 x g for 10 min and 10,000 x g for 30 min. An ultracentrifugation step of 100,000 x g 
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for 70 min was carried out to separate the soluble secretome from the extracellular vesicle (EV) 
fraction. The pellet containing the EVs was lysed with 8 M Urea buffer and in-solution digested with 
trypsin (Promega). The soluble fraction was acidified using 10% trifluoroacetic acid (TFA) to pH 5.0 and 
proteins enriched using Strataclean-resin (Agilent Technologies) as previously described (29). The 
eluted proteins from the resin were loaded in a 4-12% gradient NuPAGE Novex Bis-Tris gel, stained 
with instant blue and in-gel digested (56) with trypsin (Promega). For the secretome of hypoxic cCAFs 
silenced for NCBP2-AS2, ‘medium’ and ‘heavy’ SILAC labelled cells were transfected with siRNA CTL 
and siRNA NCBP2-AS2. 2x106 cells from each condition were seeded in a 10 cm dish and the CM 
prepared as described above. In this experiment, all secreted proteins and EVs were enriched with 
Strataclean-resin and in-gel digested with trypsin. 
Total proteome sample preparation 
For the analysis of the total proteome, total lysates from the same cells used for the isolation of the 
secretome were collected using 2% SDS, 100 mM TrisHCl pH 7.4 lysis buffer. Proteins were digested 
into peptides using filter-aided sample preparation using filter with 30 KDa cutoff (FASP,(57)). For the 
proteomes of cCAFs and pCAFs exposed to hypoxia, 50 µg of FASP-derived peptides were fractionated 
using strong anion exchange chromatography (SAX,(30)). For the proteome of hypoxic cCAFs silenced 
for NCBP2-AS2, 50 µg of FASP-derived peptides were fractionated using high-pH reverse phase 
StageTip fractionation as previously described (58), with minor modifications. 
nLC-MS/MS analysis 
After trypsin digestion, peptides were desalted using StageTip (59). Peptides were resuspended in 1% 
TFA, 0.2% acetic acid or formic acid buffer and injected on an EASY-nLC or 1200 system coupled online 
to an LTQ-Orbitrap Pro Elite or Q-Exactive HF, respectively, via nanoelectrospray ion source (Thermo 
Fisher scientific). Peptides were separated on a 20 cm fused silica emitter (New Objective) packed in 
house with reverse phase Reprosil Pur Basic 1.9 µm (Dr. Maisch GmbH). For peptide elution, buffer A 
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(0.1% formic acid) and Buffer B (80% ACN, 0.1% formic acid) were used. In the Orbitrap Elite, peptides 
were eluted with a flow of 200 nl/min from 5% to 30% of buffer B, in a 90 min linear gradient (for in-
gel digested peptides) and 190 min gradient (for SAX fractions and extracellular vesicles). In the Q-
Exactive HF, peptides were eluted with a flow of 300 nl/min from 5% to 30% of buffer B in a 60 min 
linear gradient. In the Orbitrap Elite, the mass range acquired for the full MS scan was 300-1,650 m/z 
with a resolution of 120,000 at 400 Th. The top ten most intense ions in the full MS were isolated for 
higher-energy collision dissociation fragmentation with a target of 40,000 ions at a resolution of 
15,000 at 400 Th). For the Q-Exactive HF, the mass range acquired for the full MS scan was 375-1,500 
m/z with a resolution of 60,000 at 250 Th. The top ten most intense ions in the full MS were isolated 
for fragmentation with a target of 50,000 ions at a resolution of 15,000 at 250 Th. MS data were 
acquired using the XCalibur software (Thermo Fisher Scientific). 
Parallel Reaction Monitoring and data analysis 
The mass spectrometer was operated in positive ion mode and used in parallel reaction monitoring 
(PRM). A data dependent experiment with inclusion list was set-up together with a full scan. The full 
scan was performed at a target value of 1E6 ions with resolution of 60,000 at m/z 200 over mass range 
of 375-1600 m/z followed by 6 PRM scans. The inclusion mass list included light or medium and heavy 
SILAC labelled NCBP2-AS2 peptides 5-18, 70-77 and 82-92. Targeted peptides were constantly 
fragmented in the HCD cell (Q-Exactive HF) or linear trap (Orbitrap Elite) and acquired into the Orbitrap 
analyzer or ion trap, respectively, at a resolution of 15,000 at 200 m/z (Q-Exactive HF). Quadrupole 
Isolation width was set to 1.2 m/z (Q-Exactive HF) or 1 m/z (Elite) and normalized collision energy of 
28 (Q-Exactive HF) or 35 (Orbitrap Elite) were used to fragment a maximum target of 1E5 ions (or 
injection time of 25 ms for the Q-Exactive HF) or 7.5E3 ions in the Elite. 
The PRM data traces of NCBP2-AS2 tryptic peptides were used for MS/MS based quantification. Raw 
data were imported into Skyline (version 4.1.0.18169), and y and b product ions chromatograms were 
extracted, summed and integrated. Only fragment ion peaks with the same retention time were used 
19 
 
for quantification. In the Transition settings menu, the “MS/MS filtering tool” was applied to all 
replicates using “Targeted” acquisition method. The product mass analyzer was set to “Orbitrap” and 
resolution to 15,000 (Q-Exactive HF) or to “QIT” with tolerance of 0.5 m/z (Elite). All matching scans 
were included in data extraction. Ion series extracted were compared to the 5 most intense product 
ions of a NCBP2-AS2 SILAC medium and heavy peptides library built with previously acquired data. For 
the siRNA, .raw files were analyzed with MaxQuant; protein quantification was according to the 
MaxQuant label-free quantification (LFQ) algorithm. 
MS data analysis 
The MS .raw files were processed with the MaxQuant software (31) version 1.5.0.36 and searched 
with the Andromeda search engine (60) with the following settings: minimal peptide length 7 amino 
acids, multiplicity 2, where the light labels were Arg6 and Lys4 and the heavy labels were Arg10 and 
Lys8; variable modifications Acetyl (Protein N-term) and Oxidation (M); fixed modification 
Carbamidomethyl (C); specificity for trypsin cleavage was required and maximum 2 missed cleavages 
were allowed. For the search of the parent mass and fragment ions, an initial mass deviation of 4.5 
ppm and 20 ppm, respectively, was required. The re-quantify parameter was enabled and match 
between runs was used between similar fractions. For identification, the false discovery rates (FDRs) 
at the protein and peptide level were set to 1%. For accurate protein quantification, only unique 
peptides with at least 2 ratio counts were used. Ratio count of 1 was used for the total proteome of 
CAFs silenced for NCBP2-AS2, to allow the quantification of NCBP2-AS2. The MaxQuant output table 
‘ProteinGroups.txt’ was uploaded in Perseus (61) (version 1.5.2.11) for downstream analysis. The data 
were filtered to remove potential contaminants, reverse peptides which match a decoy database, and 
proteins only identified by site, which corresponds to proteins identify through peptides which were 
identified only in their modified version. To assure an unambiguous identification, only proteins 
identified with at least one unique peptide were considered. The normalized SILAC Ratio was used for 
the analysis. Ratios from the ‘Reverse’ experiment were inverted. Then, ratios and intensities were 
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logarithmized, log2 and log10, respectively. When the distribution of the SILAC ratios was not centered 
on the zero, data were normalized by subtracting the median of the all SILAC ratios calculated for that 
experiment. Annotation from Gene Ontology Cellular Compartment (GOCC), Gene Ontology Biological 
Processes (GOBP), Gene Ontology Molecular Function (GOMF), Kyoto Encyclopedia of Genes and 
Genomes (KEGG) and Protein families (Pfam) databases were added. For the STRING analysis, the list 
of the regulated proteins was uploaded in STRING version 10.0 (62) and the analysis was conducted 
using the default settings. The output files were visualized with Cystoscape (Version 3.4.0) (63). 
Knockdown with siRNA  
cCAFs and pCAFs 90% confluent were harvested and 2x106 cells were used in each transfection 
accordingly to the manufacturer's protocol using the program T-20 and the Amaxa kit R (Lonza). Cells 
were transfected with 1-3 nM of the non-targeting siRNA as a control (D-001810-10-05, GE Healthcare 
Dharmacon) or with siRNAs targeting NCBP2-AS2 (NCBP2-AS2 #1: CTGGTATAGCAGGACAGTTAA; 
NCBP2-AS2 #2: CAGGCAAGATGTGTTAAGAAT) (Qiagen). Cells were used for experiments 24h after 
silencing. 
Scratch wound migration assay 
6x104 HUVECs were seeded in each well of an image lock 96-well plate (Essen Bioscience). The 
following day, wounds were made using the wound maker (Essen Bioscience) and the CM derived 
from CAFs silenced or not for NCBP2-AS2 was added. The images were acquired every 30 min for 24 h 
using Incucyte Zoom (Essen Bioscience). Relative wound density over the time was measured using 
the Incucyte Zoom software (Essen Bioscience). 
Protrusions and lamellipodia formation assay 
1x104 HUVECs were seeded on a 13 mm coverslip coated with gelatin. The following day, cells were 
starved for 4 h in EBM2. Then, cells were treated for 1 h with CM derived from hypoxic CAFs siCTL, 
siNCBP2-AS2 #1 or siNCBP2-AS2 #2. Cells were fixed in 4% PFA for 10 min, permeabilised with 0.2% 
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Triton X-100 in PBS for 5 min, blocked in 5% BSA for 5 min and incubated with anti-Cortactin antibody 
for 1 h (1:200, Millipore 4F11). For F-actin staining we used Alexa Fluor 594 Phalloidin (1:200, 
Molecular Probes, A12381). For nuclei staining DAPI was used (1:1,000 Sigma). Images were acquired 
on a Nikon A1R confocal microscope.  
EC treatment for VEGF signaling assessment 
2x106 HUVECs were seeded on a gelatin-coated 15 cm dish. The following day, cells were starved for 
4 h in EBM2 and treated for 5 min with the CM derived from hypoxic CAFs siCTL, siNCBP2-AS2 #1 or 
siNCBP2-AS2 #2. As a negative control for VEGF signaling we used cells starved in EBM2; as positive 
control, following 4 h starvation, cells were treated for 5 min with 20 ng/ml of VEGFA (Sigma). 
ELISA 
VEGFA concentration in the conditioned medium was measured using Quantikine ELISA human VEGF 
Kit (DVE00, R&D systems) according to manufacturer instructions. Each sample was analyzed in three 
technical replicates. 
Swap conditioned medium to assess VEGF levels 
The cCAFs were transfected with NCBCP2-AS2 #1 or control siRNA as described above. The CM was 
derived from 8 x 104 transfected cells cultured for 72 hours under hypoxia. After centrifugation, the 
cleared CM was used to culture new NCBCP2-AS2 #1 siRNA transfected cCAFs. After 72 hours culture 
under hypoxia, VEGFA levels in the conditioned medium were measured by ELISA (see above). VEGFA 
secretion by the media conditioning cells was accounted for by incubating the CM in adjacent empty 
wells during the experiment and subtracted from the ELISA values to give the results shown. 
Western blotting analysis 
Total lysates were obtained using a lysis buffer containing 2% SDS, 100 mM TrisHCl pH 7.4, incubated 
at 95 °C for 5 min, sonicated using a metal tip (Soniprep 150, MSE) and centrifuged at 16,000 x g for 
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10 min. Protein concentration was determined using Optiblot Bradford reagent (Abcam). 20 µg of 
proteins were separated using 4-12% gradient NuPAGE Novex Bis-Tris gel (Life technologies). Protein 
transfer was performed on methanol-activated PVDF or Nitrocellulose membrane. Membrane was 
blocked overnight in 5% non-fat milk (Marvel) or in 3% BSA (Sigma) in TBST (tris-buffered saline 
polysorbate 20) at 4 oC. The following primary antibodies were used: HIF1α (1:500, 10006421, 
Cayman), Vinculin (1:2,000, V9131, Sigma), GAPDH (1:1,000, Santa Cruz, sc48167), total VEGFR2 
(1:2,000, 55B11, CST), phospho VEGFR2 (Tyr 1175) (1:1,000, 2478S, CST), total PLC gamma (1:2,000, 
2822S, CST), phospho PLC gamma (Tyr783) (1:1,000, 2821S, CST), total ERK 1/2 (p44/42 MAPK) (1:2,000, 
9102, CST), phospho ERK 1/2  (p44/42 MAPK – Thr202/Tyr204) (1:1,000, 9106, CST), total p38 MAPK 
(1:2,000, 8690S, CST),  phospho P38 MAPK (Thr180/Tyr182), (1:2,000, 9216S, CST), total AKT (1:1,000, 
D7D11, CST), phospho-Akt (Ser473) (1:1,000, 9271, CST). LI-COR secondary antibodies (1:10,000, LI-COR 
Biosciences) or HRP-conjugated (1:5,000, NEB) were incubated for 1h at RT. Western blot images were 
acquired using an Odyssey CLx Scanner (LI-COR Biosciences) or a myECL Imager (Thermo Scientific). 
Reverse transcription polymerase chain reaction (RT-qPCR) 
The primers for RT-qPCR used in this study were designed using Primer Blast (NCBI): NCBP2-AS2 (F: 
GCGCTGAGCGATTTAGAGAC, R: ACTGTAGAGCCCGGAAGGAA), VEGFA (F: GCTACTGCCATCCAATCGAG, 
R: CATCGCATCAGGGGCACAC), STC1: (F: TCTGGTGCTGGTGATCAGTG, R: 
CACTTCAGCTGAGTTTTGAGCC), CPA4 (F: ACCTGCAGGCCCTTTTAGACA, R: 
AGGAAAGTCTGCGGCAATGT), LOXL2 (F: CCCCCTGGAGACTACCTGTT, R: TCGCTGAAGGAACCACCTAT) 
and PTX3 (F: GCCGGCAGGTTGTGAAACAG, R: ACATCTGTGGCTTTGACCCAA). Tata-binding protein (TBP 
F: AGTGACCCAGCATCACTGTTT, R: TAAGGTGGCAGGCTGTTGTT) or 18S (F: 
AGGAATTGACGGAAGGGCA, R: GGACATCTAAGGGCATCACA) were used as housekeeping genes for 
normalization. For mRNA isolation, 5x105 cells were seeded in 6-well plate. After hypoxia (1% O2, 72 
h) or DMOG (1 mM, 24h) treatment, mRNA was collected using RLT buffer (Qiagen). Total RNA 
extraction and DNase treatment were performed following the manufacturer’s instructions of the 
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RNeasy kit (Qiagen). cDNA was synthesized using iScript kit (BioRad) using 500 ng to 1 µg of RNA. cDNA 
was diluted 1:10 and 2 µl were used in each RT-qPCR reaction (technical triplicates), with 10 µl of iTAQ 
Universal SYBR Green Supermix (BioRad) and 400 nM of primers forward and reverse diluted in 8 µl 
of water. Each plate contained the appropriate non-template controls. Runs were performed in a 7500 
Fast Real Time PCR System (Applied Biosystems). 
Polysomal RNA isolation 
Cells exposed to normoxia or hypoxia for 24 h were treated with 100 μg/ml of cycloheximide for 3 min 
before harvesting. Cell pellets were lysed in lysis buffer (300 mM NaCl, 15 mM MgCl2 and 15 mM 
Tris/HCl pH 7.5, 1 mg/ml heparin sulfate, 100 μg/ml cycloheximide and 0.1% Triton X-100). Post-
nuclear lysates were layered on 10 ml of 10%–50% (w/v) sucrose gradients of gradient buffer (lysis 
buffer without Triton X-100). Gradients were centrifuged at 256,824 x g for 2 h at 4°C in a SW40Ti 
rotor (Beckman Coulter) and separated through a live absorbance 254 nm UV spectrometer (Isco). 
Gradients were separated into 10 fractions, and RNA precipitated by addition of guanidine 
hydrochloride (2.9 M final concentration) and ethanol (50% v/v). Precipitated RNA was then ethanol 
precipitated for a second time prior to use. Data is represented as total RNA quantity in fractions from 
non-translating and polysomal sections of the gradients. 
Sponge angiogenesis assay 
All mouse procedures were in accordance with ethical approval from the Institutional Animal Care and 
Research Advisory Committee of the K.U. Leuven. We used the subcutaneous sponge assay described 
in details in the JoVe protocol (43), with minor modifications. A biopsy puncher was used to obtain 6 
mm diameter sponges (Haromed, 1255889) for subcutaneous injection. Each sponge was embedded 
with 25 µl of conditioned medium produced for 48 h by hypoxic CAFs siCTL or siNCBP2-AS2. Four 
sponges per animal were subcutaneously transplanted and surgically dissected after 7 days. Each 
sponge was cut in two halves and embedded in OCT. Frozen sections of each sponge were stained for 
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blood vessels.  Meca32 (1:100, BD Biosciences, 550563) was used for the endothelial cells and Ng2 
(1:100, Abcam, AB5320) for the pericytes. Whole sections were imaged as a tile scan and were 
analyzed by a macro used in ImageJ. The channels were split before the individual images were put 
together into individual mosaic images for each channel and subsequently merged. Regions of interest 
were included or excluded from the analysis generating a ‘zone’. Meca32 colocalization with Ng2 
within the zone was measured. 
RNA scope, IHC and TMA staining 
In situ hybridization staining to detect mRNA expression in tissue sections was performed on tumors 
formalin-fixed for 24h at room temperature. The probe to detect the human NCBP2-AS2 was designed 
by Advanced Cell Diagnostics (Hs-NCBP2-AS2 gene 300031 ID: 152217). The staining of the paraffin-
embedded sections was performed following manufacturer’s instructions (Advanced Cell Diagnostics). 
Breast cancer TMA was purchased and contained single core per case (BR2082b, Insight 
Biotechnology). 108 cases were analyzed, which include invasive ductal carcinoma, lobular carcinoma, 
intraductal carcinoma and normal tissues. Cores at the border of the slide were not included in the 
analysis because they were damaged. Cores were defined positive for NCBP2-AS2 staining if positive 
cells were detected in the stromal compartment. Slides and TMA were digitized and viewed using 
Slidepath Digital Image Hub (Leica Microsystems) and quantified using Halo software (ACD). 
NCBP2-AS2 recombinant protein 
Human NCBP2-AS2 was cloned in BamHI/EcoRI of pGEX-4T-1 vector. NCBP2-AS2 was expressed as GST 
fusion protein in BL21 Codon-plus (DE3). After overnight induction at 18℃ cells were lysed and the 
protein was purified using a two-step chromatography procedure, including a GST affinity and size 
exclusion chromatography. Protein was aliquoted and stored in a buffer containing 150 mM NaCl, 20 
mM Tris PH 7.5 and 2mM DTT. 
Statistical analysis 
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GraphPad Prism version 7.0 was used for statistical analyses. For the quantification of the endothelial 
cell sprouting, first the distribution of the data was evaluated using the D’Agostino & Pearson 
normality test. For data with normal distribution, an unpaired two-tailed t-test with Welch’s correction 
was used. When the distribution was not normal, the Mann-Whitney t-test was used. For other 
experiments, the two-tailed unpaired t-test with Welch’s correction was used to compare samples. 
For cases in which samples were normalized to a control group, the normalized data were first log-
transformed and then a one-sample t-test (against a comparison value of 0) was performed on the 
resulting log-transformed data. For the cortactin quantification, Kruskal-Wallis test with Dunn’s 
multiple comparison test was performed. P ≤ 0.05 was considered significant. Data are represented 
as mean ± standard error of the mean (SEM), unless stated otherwise. Data in the plot were obtained 
from three biological replicates, unless stated otherwise. For the MS proteomic data analysis the 
Perseus software was used: we required proteins to be quantified in at least 2 out of 3 biological 
replicates. Then, the SILAC ratios of these quantified proteins were averaged by the mean. For the 
cCAF and pCAF hypoxia-induced proteome and secretome, the threshold to define significantly up-
regulated and down-regulated proteins was defined to be higher than one and two standard deviation 
from the mean of the SILAC ratios. This relaxed statistical threshold was chosen because known HIF1α 
responsive genes were found regulated within this threshold. For the NCBP2-AS2 knockdown 
experiment, one-sample t-test analysis was performed to ease visualization of the results with volcano 
plot. 
Supplementary Materials 
Figure S1. Response of CAFs to hypoxia. 
Figure S2. Hypoxia remodels the secretome of CAFs to promote angiogenesis. 
Figure S3. Hypoxia-responsive proteins discovered in our study. 
Figure S4. NCBP2-AS2 identification and quantification. 
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Figure S5. NCBP2-AS2 regulation by hypoxia. 
Figure S6. PRM of NCBP2-AS2 in pulsed-SILAC and siRNA experiment. 
Figure S7. Extracellular NCBP2-AS2 does not induce sprouting in ECs and VEGF expression in CAF. 
Figure S8. Western blot quantification of VEGFR-signaling in HUVECs. 
Figure S9. NCBP2-AS2 gene expression levels do not correlate with hypoxia in tumors. 
Data File S1. Proteome and secretome analysis of mammary CAFs. 
Data File S2. Hypoxia regulated proteins in CAFs. 
Data File S3. Proteome of CAFs expressing siNCBP2-AS2. 
Data File S4. Secretome of CAFs expressing siNCBP2-AS2. 
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Figure legends 
Figure 1. The secretome of hypoxic CAFs induces endothelial sprouting angiogenesis. 
(A) Scheme of the 3D fibrin-based sprouting assay for ECs co-cultured with CAFs or alone and treated 
with CAF-derived CM. (B) Representative images and quantification of the sprouting of ECs co-cultured 
with CAFs under normoxia and hypoxia for 72h. Scale bar = 50 µm. N = beads assessed in 3 biological 
replicates; cCAF normoxia n = 120, cCAF hypoxia n = 135, pCAF normoxia n = 128, pCAF hypoxia n = 
134. (C) Representative image and quantification of the sprouting of ECs treated with CM derived from 
CAFs cultured under normoxia or hypoxia for 72 h. Scale bar = 50 µm. N = beads assessed in 3 biological 
replicates; cCAFnormoxia n = 201, cCAF hypoxia n = 195, pCAF normoxia n = 112, pCAF hypoxia n = 
135. (D) RT-qPCR analysis showing VEGFA transcription in cCAFs and pCAFs under hypoxic condition 
(normalized to the VEGFA levels in normoxia condition. VEGFA normoxia = 1 = dashed line). VEGFA 
mRNA levels were normalized to TBP. N = 3 biological replicates, one-sample t-test. (E) ELISA showing 
VEGFA levels in the CM from cCAFs and pCAFs. N = 2 biological replicates. (F) Quantification of the 
sprouting of ECs treated with the CM from normoxic and hypoxic CAFs in the presence or 1 µg/ml of 
bevacizumab or IgGK (control). N = beads assessed in 3 biological replicates; CM normoxia + IgGK n = 
178, CM hypoxia + IgGK n = 161, CM normoxia + bevacizumab n = 176, CM hypoxia + bevacizumab n 
= 179. T-test. * p < 0.05, ** p < 0.01**** p < 0.0001. 
Figure 2. Hypoxia-induced remodeling of the proteome and secretome of mammary CAFs. 
(A) SILAC-based workflow used to characterize the total proteome and secretome of hypoxic cCAFs 
and pCAFs. (B) Physical and functional relationship among the hypoxia-regulated proteins in the 
intracellular proteome and secretome, as determined by STRING analysis and visualized with 
Cytoscape. GO categories and KEGG pathways enriched in the subset of proteins up-regulated and 
down-regulated by hypoxia are indicated on the right. FASP: Filter-aided sample preparation; SAX: 
strong anion exchange. Results from n=3 biological replicates for both cCAF and pCAF. 
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Figure 3. Hypoxic CAFs increase NCBP2-AS2 protein levels through enhanced translation. 
(A, B) Scatter plot of the average SILAC ratio, hypoxia/normoxia, measured by MS in the pCAF and 
cCAF proteome (A) and secretome (B) highlighting the induction of NCBP2-AS2 by hypoxia in both cell 
types. Results from n=3 biological replicates. (C) RT-qPCR showing mRNA levels of NCBP2-AS2 and 
VEGFA normalized to TBP in CAFs upon exposure to hypoxia for 72 h (normalized to the levels in CAFs 
in normoxia. Normoxia = 1 = dashed line). VEGFA was used as a positive control. N = 3 biological 
replicates. One sample t-test. (D) RT-qPCR showing the mRNA levels of NCBP2-AS2 and VEGFA upon 
treatment with 1 mM DMOG for 24 h (normalized to the levels in DMSO control-treated cells. DMSO 
= 1 = dashed line). The mRNA levels were normalized to TBP. VEGFA was used as a positive control. N 
= 3 biological replicates. One-sample t-test. (E) Polysomal profiling of cCAFs exposed to hypoxia and 
normoxia for 24 h. Representative of 3 biological replicates. (F) RT-qPCR analysis for NCBP2-AS2 and 
actin mRNAs, which was used as control, on the non-translating and polysomal ribosomal fractions. N 
= 3 biological replicates. T-test. * p < 0.05, ** p < 0.01, NS: not significant.  
Figure 4. The CM from hypoxic CAFs silenced for NCBP2-AS2 show a decreased pro-angiogenic 
activity in vitro and in vivo. 
(A, C) Sprouting quantification of ECs treated with CM from hypoxic and normoxic cCAFs (A) or pCAFs 
(C) transfected with siCTL or siNCBP2-AS2 (2 different siRNAs). N = beads assessed in 3 biological 
replicates; cCAF Hypoxic CM: siCTL n = 129, siNCBP2-AS2 #1 n = 124 and siNCBP2-AS2 #2 n = 116. 
Normoxic CM: siCTL n = 121, siNCBP2-AS2 #1 n = 131 and siNCBP2-AS2 #2 n = 122. pCAF Hypoxic CM: 
siCTL n= 119, siNCBP2-AS2 #1 = 107 and siNCBP2-AS2 #2 = 97. Normoxic CM: siCTL n= 111 beads, 
siNCBP2-AS2 #1 = 127 and siNCBP2-AS2 #2 = 104. (B, D) RT-qPCR showing the remaining mRNA levels 
of NCBP2-AS2 normalized to TBP in (B) cCAFs and (D) pCAFs used to produce CM. (E) Vascular density 
quantification, as measured by Meca32+ and Ng2+ staining of the blood vessels (y axis), of 
subcutaneous sponges which were embedded with CM derived from hypoxic CAFs transfected with 
siCTL or siNCBP2-AS2. N = ½ sponges derived from 6 mice per group. T-test. (F) RT-qPCR showing the 
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remaining mRNA levels of NCBP2-AS2 normalized to TBP in CAFs producing the CM used in the sponge 
assay in (E). * p < 0.05, *** p < 0.001, **** p < 0.0001, NS: not significant. 
Figure 5. ECs treated with the CM from hypoxic CAFs silenced for NCBP2-AS2 have a decreased 
migratory capacity. 
(A) Proliferation of ECs cultured in 2D and treated with the CM from normoxic and hypoxic CAFs 
transfected with siCTL or siNCBP2-AS2. N = 45 fields assessed per condition from 3 biological 
replicates. (B) Proliferation of ECs cultured in 3D fibrin gel and treated with the CM from normoxic and 
hypoxic CAFs transfected with siCTL or siNCBP2-AS2. N = beads assessed from 3 biological replicates. 
Normoxic CM: siCTL n = 124, siNCBP2-AS2 #1 n = 132 and siNCBP2-AS2 #2 n = 136. Hypoxic CM: siCTL 
n = 127, siNCBP2-AS2 #1 n = 120 and siNCBP2-AS2 #2 n = 134. (C) RT-qPCR showing remaining mRNA 
levels of NCBP2-AS2 normalized to TBP. (D) RT-qPCR showing remaining mRNA levels of NCBP2-AS2 
normalized to TBP. (E,F) Scratch wound migration assay using ECs treated with the CM from hypoxic 
(E) or normoxic (F) cCAFs transfected with siCTL or siNCBP2-AS2. N = 2 biological replicates. (G) 
Relative wound density measured at 12h in the two independent replicate experiments (dashed line 
in E and F). (H) Representative images of lamellipodia formation in ECs treated with the CM from cCAFs 
silenced or not for NCBP2-AS2. (I) Quantification of cortactin at the cell membrane. (J) Quantification 
of the total cell perimeter. N= cells measured in 3 biological replicates. siCTL n = 111, siNCBP2-AS2 #1 
n = 126 and siNCBP2-AS2 #2 n = 125. Scale bar = 10µm, scale bar in zoomed inset = 5µm. P-value based 
on Kruskal-Wallis test corrected for multiple testing using Dunn’s test. T-test was used for the other 
panels. ** p < 0.01, **** p < 0.0001, NS: not significant. 
Figure 6. NCBP2-AS2 regulates the levels of CAF-derived VEGFA. 
(A,B) Volcano plot showing the SILAC ratio of the proteins quantified in the total proteome (A) and 
secretome (B) of hypoxic cCAFs transfected with siCTL and siNCBP2-AS2. The dashed lines show the 
regulation cut-off of at least 1-fold change and p-value < 0.05. Results from 3 biological replicates. (C) 
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ELISA of VEGFA in the CM from hypoxic CAFs silenced or not for NCBP2-AS2 and normoxic CAFs siCTL. 
One-tailed t-test. N = biological replicates. (D) RT-qPCR showing remaining mRNA levels of NCBP2-AS2 
normalized to TBP in cells used in (C). (E) RT-qPCR for VEGFA in hypoxic cCAFs and pCAFs transfected 
with siCTL or siNCBP2-AS2. The mRNA levels were normalized to TBP. One-sample t-test. N = biological 
replicates. (F) RT-qPCR for NCBP2-AS2 showing the silencing efficiency in cells used in (E). NCBP2-AS2 
mRNA levels were normalized to TBP. N = biological replicates. (G) Influence of NCBP2-AS2 silencing 
on the angiogenic secretome of hypoxic CAFs. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p<0.0001. 
Figure 7. NCBP2-AS2 regulates EC sprouting through VEGFA signaling. 
(A) Sprouting quantification of ECs treated with the CM from hypoxic cCAFs transfected with siCTL or 
siNCBP2-AS2 (two different siRNAs) with or without VEGFA. N = beads assessed from 3 biological 
replicates. CM without VEGFA: siCTL n = 149, siNCBP2-AS2 #1 n = 128 and siNCBP2-AS2 #2 n = 110. 
CM with VEGFA: siCTL n=132, siNCBP2-AS2 #1 n = 130 and siNCBP2-AS2 #2 n = 126. (B) Sprouting 
quantification of ECs treated with the CM from hypoxic pCAFs transfected with siCTL or siNCBP2-AS2 
(two different siRNAs) with or without VEGFA. N = beads assessed from 3 biological replicates. CM 
without VEGFA: siCTL n = 162 beads, siNCBP2-AS2 #1 n = 132 and siNCBP2-AS2 #2 n = 124. CM with 
VEGFA:  siCTL n=127, siNCBP2-AS2 #1 n = 133 and siNCBP2-AS2 #2 n = 136. (C) RT-qPCR showing 
remaining mRNA levels of NCBP2-AS2 normalized to TBP. (D) Sprouting quantification of ECs treated 
with the CM from hypoxic cCAFs transfected with siCTL or siNCBP2-AS2 (two different siRNAs) in the 
presence of bevacizumab or IgGK (control). N = beads assessed from 3 biological replicates. CM with 
IgG: siCTL n = 135, siNCBP2-AS2 #1 n = 129 and siNCBP2-AS2 #2 n = 107. CM with bevacizumab: siCTL 
n = 127, siNCBP2-AS2 #1 n = 147 and siNCBP2-AS2 #2 n = 122. (E) Sprouting quantification of ECs 
treated with the CM from hypoxic pCAFs transfected with siCTL or siNCBP2-AS2 (two different siRNAs) 
in the presence of bevacizumab or IgGK (control). N = beads assessed from 3 biological replicates. CM 
with IgG: siCTL n = 121, siNCBP2-AS2 #1 n = 108 and siNCBP2-AS2 #2 n = 107. CM with bevacizumab: 
siCTL n = 126, siNCBP2-AS2 #1 n = 130 and siNCBP2-AS2 #2 n = 110. (F) RT-qPCR showing the remaining 
36 
 
mRNA levels of NCBP2-AS2 normalized to TBP. (G) Representative western blot for proteins 
downstream of VEGFR signaling in ECs treated with the CM from cCAFs silenced or not for NCBP2-AS2. 
N = 3 biological replicates. (H) RT-qPCR showing remaining mRNA levels of NCBP2-AS2 normalized to 
TBP. (I) Working model. T-test. * p < 0.05, ** p < 0.01, **** p < 0.0001, NS: not significant. 
Figure 8. NCBP2-AS2 is expressed in the stroma of breast tumors. 
(A) Pie chart showing for each type of breast cancer contained in a breast cancer TMA of 100 patient 
samples, how many showed a positive staining (as assessed by in situ hybridization with RNAscope) 
for NCBP2-AS2 in the tumor stroma. (B) Representative images of breast cancer tissues with positive 
or negative staining (as assessed by in situ hybridization with RNAscope) for NCBP2-AS2 in the tumor 
stroma. Scale bar = 100 µm for the panels on the left and 10 µm for the panels on the right. 
